Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
Carcinoma, Non-Small-Cell Lung
Protein Kinase Inhibitors
Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement. (Funded by Pfizer; ClinicalTrials.gov number, NCT00932893.).